Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Enobosarm in AR+ TNBC
NCT02971761Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enobosarm in triple-negative breast cancer (TNBC), sponsored by City of Hope. Primary endpoints: Safety and Tolerability and Response Rate at 36 months. Started Jun 2017; status: completed.
02
Drugs
enobosarm
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02971761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971761.